Selecta Biosciences, Inc. (SELB)
| Market Cap | 473.28M |
| Revenue (ttm) | 11.30M |
| Net Income (ttm) | -68.32M |
| Shares Out | 105.33M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $4.22 |
| Previous Close | $4.28 |
| Change ($) | -0.06 |
| Change (%) | -1.40% |
| Day's Open | 4.22 |
| Day's Range | 4.20 - 4.38 |
| Day's Volume | 839,659 |
| 52-Week Range | 1.42 - 5.70 |
- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector -
– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy –
Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S...
- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to...
WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogeni...
Selecta was down due to unclear results from the COMPARE trial. Management attributes poor data to noncompliance due to covid-19, among other things.
SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company"), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), th...
The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Diseas...
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2020 Results - Earnings Call Transcript
Selecta (SELB) beat estimates for both earnings and revenues in the third quarter of 2020.
WATERTOWN, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogen...
WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapi...
In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
Selecta Biosciences (SELB) news for Monday includes insider buying from a Board of Directors member sending SELB stock higher. The post Selecta Biosciences News: SELB Stock Shoots 9% Higher on...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
These are the stocks seeing the most insider buying this week
In his weekly exclusive for Worldwide Exchange, Brian Sullivan highlights three stocks seeing the most insider buying this week, including some biotech names.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
Application of ImmTOR™ plus IGAN’s IgA p rotease to target immunoglobulin A ( IgA ) deposition, the critical event leading to IgA N ephropathy ( IgAN )
With a market cap of $171 million (10/1/2020), Selecta Biosciences is a well positioned clinical-stage biotech company, focusing on immunogenicity.
Shares of Horizon Therapeutics PLC (NASDAQ: HZNP), which focuses on rare and rheumatic diseases, surged higher Thursday despite an absence of announcements from the biopharma. What Happened: H...
Disappointing phase 2 data casts doubt on SEL-212's future.
STOCKHOLM and WATERTOWN, Mass., Sept. 30, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data...
All data consistent with stronger performance of SEL-212 versus pegloticase
WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic ther...
STOCKHOLM and WATERTOWN, Mass., Sept. 23, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commenceme...
STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced ...
WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic ther...
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2020 Results - Earnings Call Transcript
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -153.13% and -100.00%, respectively, for the quarter ended June 2020.
Selecta Biosciences (SELB) miss estimates for earnings and revenues in the second quarter of 2020.
WATERTOWN, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic thera...
In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic thera...
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic thera...
STOCKHOLM, Sweden and WATERTOWN, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI ) today announced that the strategic licensing agreement with ...
Is (SELB) Outperforming Other Medical Stocks This Year?
These two healthcare stocks are risky, but they have much better chances of success than penny stocks.
Partnership strategy for ImmTOR platform continues to pay off with Sarepta deal immediately following $100 million upfront Sobi deal.
Selecta Biosciences (SELB) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Selecta Biosciences Inc. (NASDAQ: SELB) and Sarepta Therapeutics Inc. (NASDAQ: SRPT) have announced that they had entered into a research license and option agreement.
Application of ImmTOR plus Sarepta’s investigational gene therapies will be evaluated for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophies Application of ImmTOR plus Sarepta’s ...
It's Time To Invest In Selecta Biosciences As They Ink Massive $100 Million Upfront Deal
Is (SELB) Outperforming Other Medical Stocks This Year?
WATERTOWN, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic thera...
A licensing deal for a late-stage asset failed to impress Wall Street. One analyst went as far as downgrading the biopharma stock.
STOCKHOLM, and WATERTOWN, Mass., June 11, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced that the compa...
About SELB
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in prec... [Read more...]
| Industry Biotechnology | IPO Date Jun 22, 2016 |
| CEO Carsten Brunn | Employees 39 |
| Stock Exchange NASDAQ | Ticker Symbol SELB |
Financial Performance
In 2019, SELB's revenue was $6.68 million, an increase of 639.42% compared to the previous year's $903,000. Losses were -$55.35 million, -15.28% less than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for SELB stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 77.73% from the latest price.